Tango Therapeutics Inc. (TNGX)
Tango Therapeutics Statistics
Share Statistics
Tango Therapeutics has 108.11M shares outstanding. The number of shares has increased by 1.18% in one year.
| Shares Outstanding | 108.11M |
| Shares Change (YoY) | 1.18% |
| Shares Change (QoQ) | 0.64% |
| Owned by Institutions (%) | 98.1% |
| Shares Floating | 59.12M |
| Failed to Deliver (FTD) Shares | 1.9K |
| FTD / Avg. Volume | 0.24% |
Short Selling Information
The latest short interest is 7.02M, so 6.53% of the outstanding shares have been sold short.
| Short Interest | 7.02M |
| Short % of Shares Out | 6.53% |
| Short % of Float | 14.08% |
| Short Ratio (days to cover) | 5.58 |
Valuation Ratios
The PE ratio is -2.59 and the forward PE ratio is -2.17. Tango Therapeutics's PEG ratio is -0.25.
| PE Ratio | -2.59 |
| Forward PE | -2.17 |
| PS Ratio | 8.02 |
| Forward PS | 3.4 |
| PB Ratio | 1.69 |
| P/FCF Ratio | -2.57 |
| PEG Ratio | -0.25 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tango Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.98, with a Debt / Equity ratio of 0.18.
| Current Ratio | 6.98 |
| Quick Ratio | 6.98 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.25 |
| Debt / FCF | -0.28 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $271.41K |
| Profits Per Employee | $-840.66K |
| Employee Count | 155 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 208K |
| Effective Tax Rate | -0.16% |
Stock Price Statistics
The stock price has increased by -82.16% in the last 52 weeks. The beta is 0.87, so Tango Therapeutics's price volatility has been higher than the market average.
| Beta | 0.87 |
| 52-Week Price Change | -82.16% |
| 50-Day Moving Average | 2.28 |
| 200-Day Moving Average | 5.75 |
| Relative Strength Index (RSI) | 29.74 |
| Average Volume (20 Days) | 791.09K |
Income Statement
In the last 12 months, Tango Therapeutics had revenue of 42.07M and earned -130.3M in profits. Earnings per share was -1.19.
| Revenue | 42.07M |
| Gross Profit | 42.07M |
| Operating Income | -145.59M |
| Net Income | -130.3M |
| EBITDA | -145.59M |
| EBIT | -145.59M |
| Earnings Per Share (EPS) | -1.19 |
Balance Sheet
The company has 69.53M in cash and 36.49M in debt, giving a net cash position of 33.04M.
| Cash & Cash Equivalents | 69.53M |
| Total Debt | 36.49M |
| Net Cash | 33.04M |
| Retained Earnings | -501.56M |
| Total Assets | 316.49M |
| Working Capital | 228.17M |
Cash Flow
In the last 12 months, operating cash flow was -131.5M and capital expenditures 0, giving a free cash flow of -131.5M.
| Operating Cash Flow | -131.5M |
| Capital Expenditures | 0 |
| Free Cash Flow | -131.5M |
| FCF Per Share | -1.2 |
Margins
Gross margin is 100%, with operating and profit margins of -346.09% and -309.73%.
| Gross Margin | 100% |
| Operating Margin | -346.09% |
| Pretax Margin | -309.24% |
| Profit Margin | -309.73% |
| EBITDA Margin | -346.09% |
| EBIT Margin | -346.09% |
| FCF Margin | -312.58% |
Dividends & Yields
TNGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TNGX is $13, which is 848.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $13 |
| Price Target Difference | 848.9% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -1.98 |
| Piotroski F-Score | 2 |